Suppr超能文献

对于无法切除且侵犯肝内大血管的晚期肝细胞癌患者,放射治疗作为初始治疗的潜在预后益处。

Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels.

作者信息

Nakazawa Takahide, Adachi Shigeru, Kitano Masashi, Isobe Yoshinori, Kokubu Shigehiro, Hidaka Hisashi, Ono Koji, Okuwaki Yusuke, Watanabe Masaaki, Shibuya Akitaka, Saigenji Katsunori

机构信息

Gastroenterology Division of Internal Medicine, Kitasato University East Hospital, Sagamihara, Japan.

出版信息

Oncology. 2007;73(1-2):90-7. doi: 10.1159/000120996. Epub 2008 Mar 13.

Abstract

OBJECTIVES

To examine the efficacy and prognostic benefits of radiotherapy (RT) in patients who have unresectable advanced hepatocellular carcinoma (HCC) with invasion to intrahepatic large vessels (IHLVs).

METHODS

Sixty-eight patients who had advanced HCC with invasion to IHLVs were studied. Thirty-two consecutive patients initially received 3-dimensional conformal RT for HCC invasion to IHLVs. Tumor response, prognostic factors, and survival were studied in the patients given RT. Prognostic factors and survival were assessed in the study group as a whole. Data were analyzed using the Kaplan-Meier method, univariate analysis, and a Cox model.

RESULTS

The rate of objective response to RT was 48%. Predictors of survival in the patients who received RT were a hepatic function of Child-Pugh class A (p = 0.0263) and a response to RT (p = 0.0121). In the study group as a whole, independent predictors of survival in a Cox model were multinodular HCC (p = 0.007), inferior vena caval invasion (p = 0.001), a serum alpha-fetoprotein level of >1,000 ng/ml (p = 0.032), and the performance of RT (p < 0.001). Notably, the median survival of the nonresponders to RT (n = 15) was significantly longer than that of the patients who received no treatment for HCC (n = 21; 7.0 vs. 3.4 months, p = 0.0014).

CONCLUSION

RT is considered an effective initial treatment for HCC invasion to IHLVs, and may offer survival benefits, even in nonresponders, because of the induction of stable disease.

摘要

目的

探讨放疗(RT)对无法切除的晚期肝细胞癌(HCC)侵犯肝内大血管(IHLV)患者的疗效及预后益处。

方法

对68例晚期HCC侵犯IHLV的患者进行研究。连续32例患者最初接受针对HCC侵犯IHLV的三维适形放疗。对接受放疗的患者研究肿瘤反应、预后因素和生存率。对整个研究组评估预后因素和生存率。使用Kaplan-Meier法、单因素分析和Cox模型分析数据。

结果

放疗的客观缓解率为48%。接受放疗患者的生存预测因素为Child-Pugh A级肝功能(p = 0.0263)和对放疗的反应(p = 0.0121)。在整个研究组中,Cox模型中生存的独立预测因素为多结节HCC(p = 0.007)、下腔静脉侵犯(p = 0.001)、血清甲胎蛋白水平>1000 ng/ml(p = 0.032)和放疗的实施(p < 0.001)。值得注意的是,放疗无反应者(n = 15)的中位生存期显著长于未接受HCC治疗的患者(n = 21;7.0个月对3.4个月,p = 0.0014)。

结论

放疗被认为是HCC侵犯IHLV的一种有效初始治疗方法,即使对无反应者也可能带来生存益处,因为可诱导疾病稳定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验